List of Tables
Table 1. Meningococcal Disease Vaccine Market Trends
Table 2. Meningococcal Disease Vaccine Market Drivers & Opportunity
Table 3. Meningococcal Disease Vaccine Market Challenges
Table 4. Meningococcal Disease Vaccine Market Restraints
Table 5. Global Meningococcal Disease Vaccine Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Meningococcal Disease Vaccine Revenue Market Share by Company (2019-2024)
Table 7. Global Meningococcal Disease Vaccine Sales Volume by Company (2019-2024) & (K Units)
Table 8. Global Meningococcal Disease Vaccine Sales Volume Market Share by Company (2019-2024)
Table 9. Global Market Meningococcal Disease Vaccine Price by Company (2019-2024) & (US$/Unit)
Table 10. Key Manufacturers Meningococcal Disease Vaccine Manufacturing Base Distribution and Headquarters
Table 11. Key Manufacturers Meningococcal Disease Vaccine Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of Meningococcal Disease Vaccine
Table 13. Global Meningococcal Disease Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Meningococcal Disease Vaccine as of 2023)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Meningococcal Disease Vaccine Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 17. Global Meningococcal Disease Vaccine Sales Value by Type (2019-2024) & (US$ Million)
Table 18. Global Meningococcal Disease Vaccine Sales Value by Type (2025-2030) & (US$ Million)
Table 19. Global Meningococcal Disease Vaccine Sales Market Share in Value by Type (2019-2024) & (%)
Table 20. Global Meningococcal Disease Vaccine Sales Market Share in Value by Type (2025-2030) & (%)
Table 21. Global Meningococcal Disease Vaccine Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
Table 22. Global Meningococcal Disease Vaccine Sales Volume by Type (2019-2024) & (K Units)
Table 23. Global Meningococcal Disease Vaccine Sales Volume by Type (2025-2030) & (K Units)
Table 24. Global Meningococcal Disease Vaccine Sales Market Share in Volume by Type (2019-2024) & (%)
Table 25. Global Meningococcal Disease Vaccine Sales Market Share in Volume by Type (2025-2030) & (%)
Table 26. Global Meningococcal Disease Vaccine Price by Type (2019-2024) & (US$/Unit)
Table 27. Global Meningococcal Disease Vaccine Price by Type (2025-2030) & (US$/Unit)
Table 28. Global Meningococcal Disease Vaccine Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 29. Global Meningococcal Disease Vaccine Sales Value by Application (2019-2024) & (US$ Million)
Table 30. Global Meningococcal Disease Vaccine Sales Value by Application (2025-2030) & (US$ Million)
Table 31. Global Meningococcal Disease Vaccine Sales Market Share in Value by Application (2019-2024) & (%)
Table 32. Global Meningococcal Disease Vaccine Sales Market Share in Value by Application (2025-2030) & (%)
Table 33. Global Meningococcal Disease Vaccine Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)
Table 34. Global Meningococcal Disease Vaccine Sales Volume by Application (2019-2024) & (K Units)
Table 35. Global Meningococcal Disease Vaccine Sales Volume by Application (2025-2030) & (K Units)
Table 36. Global Meningococcal Disease Vaccine Sales Market Share in Volume by Application (2019-2024) & (%)
Table 37. Global Meningococcal Disease Vaccine Sales Market Share in Volume by Application (2025-2030) & (%)
Table 38. Global Meningococcal Disease Vaccine Price by Application (2019-2024) & (US$/Unit)
Table 39. Global Meningococcal Disease Vaccine Price by Application (2025-2030) & (US$/Unit)
Table 40. Global Meningococcal Disease Vaccine Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Global Meningococcal Disease Vaccine Sales Value by Region (2019-2024) & (US$ Million)
Table 42. Global Meningococcal Disease Vaccine Sales Value by Region (2025-2030) & (US$ Million)
Table 43. Global Meningococcal Disease Vaccine Sales Value by Region (2019-2024) & (%)
Table 44. Global Meningococcal Disease Vaccine Sales Value by Region (2025-2030) & (%)
Table 45. Global Meningococcal Disease Vaccine Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
Table 46. Global Meningococcal Disease Vaccine Sales Volume by Region (2019-2024) & (K Units)
Table 47. Global Meningococcal Disease Vaccine Sales Volume by Region (2025-2030) & (K Units)
Table 48. Global Meningococcal Disease Vaccine Sales Volume by Region (2019-2024) & (%)
Table 49. Global Meningococcal Disease Vaccine Sales Volume by Region (2025-2030) & (%)
Table 50. Global Meningococcal Disease Vaccine Average Price by Region (2019-2024) & (US$/Unit)
Table 51. Global Meningococcal Disease Vaccine Average Price by Region (2025-2030) & (US$/Unit)
Table 52. Key Countries/Regions Meningococcal Disease Vaccine Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 53. Key Countries/Regions Meningococcal Disease Vaccine Sales Value, (2019-2024) & (US$ Million)
Table 54. Key Countries/Regions Meningococcal Disease Vaccine Sales Value, (2025-2030) & (US$ Million)
Table 55. Key Countries/Regions Meningococcal Disease Vaccine Sales Volume, (2019-2024) & (K Units)
Table 56. Key Countries/Regions Meningococcal Disease Vaccine Sales Volume, (2025-2030) & (K Units)
Table 57. AstraZeneca Company Information
Table 58. AstraZeneca Introduction and Business Overview
Table 59. AstraZeneca Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 60. AstraZeneca Meningococcal Disease Vaccine Product Offerings
Table 61. AstraZeneca Recent Development
Table 62. Johnson & Johnson Company Information
Table 63. Johnson & Johnson Introduction and Business Overview
Table 64. Johnson & Johnson Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 65. Johnson & Johnson Meningococcal Disease Vaccine Product Offerings
Table 66. Johnson & Johnson Recent Development
Table 67. Mylan N.V Company Information
Table 68. Mylan N.V Introduction and Business Overview
Table 69. Mylan N.V Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 70. Mylan N.V Meningococcal Disease Vaccine Product Offerings
Table 71. Mylan N.V Recent Development
Table 72. Teva Pharmaceutical Industries Ltd Company Information
Table 73. Teva Pharmaceutical Industries Ltd Introduction and Business Overview
Table 74. Teva Pharmaceutical Industries Ltd Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 75. Teva Pharmaceutical Industries Ltd Meningococcal Disease Vaccine Product Offerings
Table 76. Teva Pharmaceutical Industries Ltd Recent Development
Table 77. Pfizer Inc Company Information
Table 78. Pfizer Inc Introduction and Business Overview
Table 79. Pfizer Inc Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 80. Pfizer Inc Meningococcal Disease Vaccine Product Offerings
Table 81. Pfizer Inc Recent Development
Table 82. GlaxoSmithKline plc Company Information
Table 83. GlaxoSmithKline plc Introduction and Business Overview
Table 84. GlaxoSmithKline plc Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 85. GlaxoSmithKline plc Meningococcal Disease Vaccine Product Offerings
Table 86. GlaxoSmithKline plc Recent Development
Table 87. Novartis AG Company Information
Table 88. Novartis AG Introduction and Business Overview
Table 89. Novartis AG Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 90. Novartis AG Meningococcal Disease Vaccine Product Offerings
Table 91. Novartis AG Recent Development
Table 92. Sanofi Company Information
Table 93. Sanofi Introduction and Business Overview
Table 94. Sanofi Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 95. Sanofi Meningococcal Disease Vaccine Product Offerings
Table 96. Sanofi Recent Development
Table 97. Merck & Co., Inc. Company Information
Table 98. Merck & Co., Inc. Introduction and Business Overview
Table 99. Merck & Co., Inc. Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 100. Merck & Co., Inc. Meningococcal Disease Vaccine Product Offerings
Table 101. Merck & Co., Inc. Recent Development
Table 102. F. Hoffmann-La Roche Ltd Company Information
Table 103. F. Hoffmann-La Roche Ltd Introduction and Business Overview
Table 104. F. Hoffmann-La Roche Ltd Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 105. F. Hoffmann-La Roche Ltd Meningococcal Disease Vaccine Product Offerings
Table 106. F. Hoffmann-La Roche Ltd Recent Development
Table 107. Baxter Company Information
Table 108. Baxter Introduction and Business Overview
Table 109. Baxter Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 110. Baxter Meningococcal Disease Vaccine Product Offerings
Table 111. Baxter Recent Development
Table 112. BIO-MED Company Information
Table 113. BIO-MED Introduction and Business Overview
Table 114. BIO-MED Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 115. BIO-MED Meningococcal Disease Vaccine Product Offerings
Table 116. BIO-MED Recent Development
Table 117. Bio-Manguinhos Company Information
Table 118. Bio-Manguinhos Introduction and Business Overview
Table 119. Bio-Manguinhos Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 120. Bio-Manguinhos Meningococcal Disease Vaccine Product Offerings
Table 121. Bio-Manguinhos Recent Development
Table 122. Walvax Biotechnology Co., Ltd Company Information
Table 123. Walvax Biotechnology Co., Ltd Introduction and Business Overview
Table 124. Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 125. Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Product Offerings
Table 126. Walvax Biotechnology Co., Ltd Recent Development
Table 127. Key Raw Materials Lists
Table 128. Raw Materials Key Suppliers Lists
Table 129. Meningococcal Disease Vaccine Downstream Customers
Table 130. Meningococcal Disease Vaccine Distributors List
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources
List of Figures
Figure 1. Meningococcal Disease Vaccine Product Picture
Figure 2. Global Meningococcal Disease Vaccine Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Meningococcal Disease Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 4. Global Meningococcal Disease Vaccine Sales Volume (2019-2030) & (K Units)
Figure 5. Global Meningococcal Disease Vaccine Sales Price (2019-2030) & (US$/Unit)
Figure 6. Meningococcal Disease Vaccine Report Years Considered
Figure 7. Global Meningococcal Disease Vaccine Players Revenue Ranking (2023) & (US$ Million)
Figure 8. Global Meningococcal Disease Vaccine Players Sales Volume Ranking (2023) & (K Units)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Meningococcal Disease Vaccine Revenue in 2023
Figure 10. Meningococcal Disease Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 11. Polysaccharide Picture
Figure 12. Conjugate Picture
Figure 13. Combination Picture
Figure 14. Global Meningococcal Disease Vaccine Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 15. Global Meningococcal Disease Vaccine Sales Value Market Share by Type, 2023 & 2030
Figure 16. Global Meningococcal Disease Vaccine Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
Figure 17. Global Meningococcal Disease Vaccine Sales Volume Market Share by Type, 2023 & 2030
Figure 18. Global Meningococcal Disease Vaccine Price by Type (2019-2030) & (US$/Unit)
Figure 19. Product Picture of Infant
Figure 20. Product Picture of Child
Figure 21. Product Picture of Aldult
Figure 22. Global Meningococcal Disease Vaccine Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 23. Global Meningococcal Disease Vaccine Sales Value Market Share by Application, 2023 & 2030
Figure 24. Global Meningococcal Disease Vaccine Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
Figure 25. Global Meningococcal Disease Vaccine Sales Volume Market Share by Application, 2023 & 2030
Figure 26. Global Meningococcal Disease Vaccine Price by Application (2019-2030) & (US$/Unit)
Figure 27. North America Meningococcal Disease Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 28. North America Meningococcal Disease Vaccine Sales Value by Country (%), 2023 VS 2030
Figure 29. Europe Meningococcal Disease Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 30. Europe Meningococcal Disease Vaccine Sales Value by Country (%), 2023 VS 2030
Figure 31. Asia Pacific Meningococcal Disease Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 32. Asia Pacific Meningococcal Disease Vaccine Sales Value by Country (%), 2023 VS 2030
Figure 33. South America Meningococcal Disease Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 34. South America Meningococcal Disease Vaccine Sales Value by Country (%), 2023 VS 2030
Figure 35. Middle East & Africa Meningococcal Disease Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 36. Middle East & Africa Meningococcal Disease Vaccine Sales Value by Country (%), 2023 VS 2030
Figure 37. Key Countries/Regions Meningococcal Disease Vaccine Sales Value (%), (2019-2030)
Figure 38. Key Countries/Regions Meningococcal Disease Vaccine Sales Volume (%), (2019-2030)
Figure 39. United States Meningococcal Disease Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 40. United States Meningococcal Disease Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 41. United States Meningococcal Disease Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 42. Europe Meningococcal Disease Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 43. Europe Meningococcal Disease Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 44. Europe Meningococcal Disease Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 45. China Meningococcal Disease Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 46. China Meningococcal Disease Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 47. China Meningococcal Disease Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 48. Japan Meningococcal Disease Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 49. Japan Meningococcal Disease Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 50. Japan Meningococcal Disease Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 51. South Korea Meningococcal Disease Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 52. South Korea Meningococcal Disease Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 53. South Korea Meningococcal Disease Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 54. Southeast Asia Meningococcal Disease Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 55. Southeast Asia Meningococcal Disease Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 56. Southeast Asia Meningococcal Disease Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 57. India Meningococcal Disease Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 58. India Meningococcal Disease Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 59. India Meningococcal Disease Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 60. Meningococcal Disease Vaccine Industrial Chain
Figure 61. Meningococcal Disease Vaccine Manufacturing Cost Structure
Figure 62. Channels of Distribution (Direct Sales, and Distribution)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
